Southeast Asia Leg Of Sanofi’s Phase III Dengue Vaccine Trial Meets Primary Endpoint
This article was originally published in PharmAsia News
Executive Summary
Sanofi Pasteur says that a vaccine candidate for dengue has met its primary endpoint in Phase III trials in Southeast Asia, capping a 20-year effort that has cost more than $1 billion. The focus now is on a second leg in Latin America with a vaccine possibly ready for the market late next year if all goes according to plan.